R. BRUGNOLI, C. SILVESTRINI, L. TARSITANI , P. PANCHERI - Vol. 9, December 2003, Issue 4
Testo Immagini Bibliografia Indice
Indagine conoscitiva su un campione di psichiatri
italiani
Come, quando e perché una terapia antidepressiva
A survey of psychiatrists in Italy
The how, when, and why of antidepressant drug therapy
1 Cassano P, Fava M. Depression and public health. An overview. J Psychosom Res 2003;53:849-57.
2 Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and additive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94.
3 Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19.
4 Lepine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES [Depression Research in European Society]. Int Clin Psychopharmacol 1997;12:19-29.
5 Ustun TB, Sartorius N. Public health aspects of anxiety and depressive disorders. Int Clin Psychopharmacol 1993;8:15-20.
6 Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well being of depressed patients. JAMA 1989;262:861-73.
7 Bland RC. Epidemiology of affective disorder: a review. Can J Psychiatry 1997;42:367-77.
8 Kessler RC, Frank RG. The impact of psychiatric disorders on work loss days. Psychol Med 1997;27:861-73.
9 Goldney RD, Fisher LJ, Wilson DH, Cheok F. Major depression and its associated morbidity and quality of life in a random, representative Australian community sample. Aust N Z J Psichiatry 2000;34:1022-9.
10 Sartorious N. The economic and social burden of depression. J Clin Psychiatry 2001;62(suppl 15):8-11.
11 Panzarino PJJr. The costs of depression: direct and indirect; treatment versus non treatment. J Clin Psychiatry 1998;59:11-4.
12 Penninx BW, Geerlings SW, Deeg DJ, Van Tilburg W, Beekman AT. Minor and Major Depression and the risk of death in older persons. Arch Gen Psychiatry 1999;56:889-95.
13 Bruce ML, Leaf PJ, Rozal GP, Florio L, Hoff RA. Psychiatric status and 9-year mortality data in the New Heaven Epidemiologic Catchment Area Study. Am J Psychiatry 1994;151:716-21.
14 Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-40.
15 Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample. Am J Psychiatry 1994;151:979-86.
16 World Health Organization. The Global burden of disease. In: Murray CJL, Lopez AD (eds.) The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and projected. Cambridge, Mass: Harvard School of Public Health, 1996.
17 DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-7.
18 Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care 1993;16:1167-78.
19 Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:934-42.
20 de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63:619-30.
21 Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001;58:221-7.
22 Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001;161:1849-56.
23 Pohjasvaara T, Vataja R, Leppavuori A, Kaste M, Erkinjuntti T. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol 2001;8:315-9.
24 Everson SA, Roberts RE, Goldberg DE, Kaplan GA. Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med 1998;158:1133-8.
25 Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-40.
26 Goldberg D, Huxley P. Common mental disorder. London: Routledge, 1992.
27 Tiemeier H, de Vries WJ, van het Loo M, Kahan JP, Klazinga N, Grol R, et al. Guidelines adherence rates and interprofessional variation in a vignette study of depression. Qual Saf Health Care 2002;11:214-8.
28 World Psychiatric Association and International Committee for Prevention and Treatment of Depression. Educational program on depressive disorder: overview and fundamental aspects. New York: Nmc Publishers, Inc 1997.
29 Rosembaum JF. There is a lot of room to make things better. Ital J Psychopathol 2003;9(Suppl. 1):5-7.
30 American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(Suppl 4):1-45.
31 Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines.British Association for Psychopharmacology. J Psychopharmacol 2000;14:3-20.
32 Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992;305:1198-202.
33 Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998;44:348-60.
34 Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164-72.
35 Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ, WFSBP task force on treatment guidelines for unipolar depressive disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5-43.
36 Jenner PN. Paroxetine: an overview of dosage, tolerability, and safety. In: Mongomery SA. Selective serotonin reuptake inhibitors in psychiatric practice. Int Clin Psychopharmacol 1992; 6(Suppl 4):69-80.
37 Psychotropic Prescribing Guide. Selective serotonin reuptake inhibitors (SSRIs). Medical Economics Company, Inc. NJ, 2000, third edition.
38 Anderson IM. Selective serotonin reuptake inhibitors versus tryciclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36.
39 American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(suppl):1-45.
40 Consensus Conference della Società Italiana di Psicopatologia. Linee guida sulla farmacoterapia dei disturbi dell'umore. Giorn Ital Psicopat 1999;5(Suppl al n. 3).
41 Quitkin FM, Harrison W, Steward JW, McGrath PJ, Tricamo E, Ocepek-Welikson K, et al. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry 1991;48:319-23.
42 Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219.
43 Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M. Course and treatment of atypical depression. J Clin Psychiatry 1998;59(suppl 18):5-9.
44 Pancheri P, Biondi M. L’apatia. Dimensioni psicopatologiche e pratica clinica. Roma: Il Pensiero Scientifico Editore 1995.
45 Page ME, Lucki I. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 2002;27:237-47.
46 Linner L, Endersz H, Ohman D, Bengtsson F, Schalling M, Svensson TH. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 2001;297:540-6.